This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).

开始日期2026-05-05

申办/合作机构

Oregon Health & Science University

[+1]

NCT07023341

/ Active, not recruiting临床3期

A Phase 3, Open Label, Single Arm Study to Evaluate Efficacy, Safety and Tolerability of Aficamten in Adult Japanese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Researchers are looking for a better way to treat Japanese people who have symptomatic obstructive hypertrophic cardiomyopathy (symptomatic oHCM).
Obstructive hypertrophic cardiomyopathy (oHCM) is a type of heart disease where the heart muscles become thicker than normal due to over contraction. This thickening makes it harder than normal due to over contraction. This thickening makes it harder for the heart to pump blood out to the rest of the body. In symptomatic oHCM people with the condition experience symptoms like shortness of breath, chest pain, fainting, high blood pressure and irregular heartbeats.
The study treatment aficamten, also called BAY3723113, is under development to treat symptomatic oHCM. It aims to reduce the activity of cardiac myosin, a protein that helps heart muscles to contract, and thereby preventing over contraction and muscle thickening.
Although treatment options are available for symptomatic oHCM, there is still need for other treatment options that help target the root cause of the condition. In this study, researchers want to understand about the effects and long-term safety of aficamten in Japanese people with symptomatic oHCM.
The main purpose of the study is to learn how well aficamten works in Japanese with symptomatic oCHM.
For this, the researchers will check how participant's heart blood flow changes after 6 months of treatment. They do this by measuring the pressure needed for blood to leave the heart using a test called the left ventricular outflow tract (LVOT) gradient and a special breathing technique called Valsava maneuver.
Researchers will also look for:
* the number of participants who will have at least 1 level improvement on a scale doctors use to assess the effect of heart problems on daily activities after 3 and 6 months of treatment
* the change in the impact of heart problems on participant's daily lives based on their feedback on a questionnaire called Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS) after 3 and 6 months of treatment.
This study will have 2 treatment periods: main treatment period and long-term treatment period. During the main treatment period, participants will take aficamten tablets once daily by mouth for up to 6 months. After completing this period, the participants who can join the long-term treatment period will continue taking aficamten until the drug becomes commercially available in Japan or the study ends.
Each participant will be in the study as long as they benefit from the treatment.
Participants will visit the study site:
* once before the treatment starts
* 9 times with a gap of 2 to 4 weeks between the visits during treatment under the main treatment period, and in the long-term treatment period, participants will visit almost every 3 months until the treatment ends.
* then 2 more times with a gap of 1 month between the visits after the treatment ends.
During the study, the study doctors and their team will:
* check participant's health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram (ECG) and echocardiogram (ECHO)
* ask the participants questions about how they are feeling and what adverse events are they having
An adverse event is any medical problem that a participant has during a study. Study doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study.
If the participant benefits from the treatment, treatment with aficamten after the end of the study might be possible.

开始日期2025-06-30

申办/合作机构

Bayer AG

JPRN-jRCT2031250066

/ Recruiting临床3期

A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy. (A study of aficamten in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (ACACIA-HCM))

开始日期2025-04-14

申办/合作机构

Cytokinetics, Inc.

100 项与阿夫凯泰相关的临床结果

登录后查看更多信息

100 项与阿夫凯泰相关的转化医学

登录后查看更多信息

100 项与阿夫凯泰相关的专利（医药）

登录后查看更多信息

113

项与阿夫凯泰相关的文献（医药）

2026-07-01·AMERICAN JOURNAL OF CARDIOLOGY

Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients

Article

作者: Veselka, Josef ; Coats, Caroline J ; Nassif, Michael E ; Abraham, Theodore P ; Claggett, Brian L ; Gimeno, Ramon ; Wohltman, Amy ; Miao, Zi Michael ; Malik, Fady I ; Barriales-Villa, Roberto ; Olivotto, Iacopo ; Heitner, Stephen B ; Maron, Martin S ; Masri, Ahmad ; Kupfer, Stuart ; Januzzi, James L ; Jacoby, Daniel L ; Hegde, Sheila M

This sub-analysis of SEQUOIA-HCM (NCT05186818) evaluated the efficacy and safety of aficamten in obstructive hypertrophic cardiomyopathy (oHCM) and very-high Valsalva left ventricular outflow tract gradients (LVOT-G). Patients with oHCM and Valsalva LVOT-G ≥100 mm Hg (n = 73) were randomized to aficamten (n = 33) or placebo (n = 40) for 24 weeks. The primary endpoint was proportional change in Valsalva LVOT-G from baseline to Week 24. Secondary endpoints included the proportion of patients achieving Valsalva LVOT-G < 30 mm Hg, absolute change in Valsalva LVOT-G, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CCS), New York Heart Association (NYHA) functional class, NT-proBNP, and exercise capacity (peak oxygen uptake [pVO₂], workload), and time eligible for septal reduction therapy (SRT). Over 24 weeks, aficamten significantly reduced Valsalva LVOT-G by 66% from 123 ± 28 mm Hg to 41 ± 30 mm Hg (p = 0.001), including to <30 mm Hg in 42% of aficamten patients (p <0.001). Aficamten was also associated with symptom relief: 16 patients (48%) had ≥1 improvement in NYHA class, including 9 with both class I and ≥5-point increase in KCCQ-CSS. Compared with placebo, aficamten substantially decreased NT-proBNP concentration (‒85%; p = 0.001) and increased pVO₂ (+1.8 ml/kg/min; p = 0.003). Aficamten also reduced time eligible for SRT (p = 0.002) without any clinically relevant decrease in systolic function (ejection fraction <50%). Aficamten effectively reduced gradients in patients with oHCM and very-high Valsalva LVOT-G. Hemodynamic changes were associated with enhanced exercise capacity and symptom relief, underscoring aficamten treatment benefit across the spectrum of LVOT-G.

2026-06-23·EUROPEAN HEART JOURNAL

Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study

Article

作者: Saberi, Sara ; Wei, Jenny ; Choudhury, Lubna ; Solomon, Scott D ; Barriales-Villa, Roberto ; Liu, Xueli ; Melloni, Chiara ; Simkins, Tyrell J ; Owens, Anjali Tiku ; Oreziak, Artur ; Malik, Fady I ; Abraham, Theodore P ; Cooper, Robert M ; Heitner, Stephen B ; Nassif, Michael E ; Kupfer, Stuart ; Olivotto, Iacopo ; Elliott, Perry M ; Tower-Rader, Albree ; Maron, Martin S ; Masri, Ahmad ; Jacoby, Daniel L

Abstract:

Background and Aims:

Aficamten is a next-in-class, oral selective cardiac myosin inhibitor that ameliorates hypercontractility in hypertrophic cardiomyopathy (HCM). This study assessed the safety and efficacy of extended aficamten treatment in symptomatic obstructive HCM (oHCM).

Methods:

Patients completing a parent aficamten study were eligible to enrol in FOREST-HCM (NCT04848506), an open-label study evaluating long-term aficamten treatment.

Results:

Patients with oHCM (N = 296; mean age ±SD 61 ± 12.3 years, 44.3% female) enrolled between May 2021 and August 2024. Cumulative exposure was 352 patient-years; median follow-up 51.6 (IQR 41.5, 70.8) weeks. At Weeks 12 and 96, aficamten reduced Valsalva left ventricular outflow tract gradient by 56 ± 43 and 62 ± 33 mmHg from baseline (both P < 0.0001), with minimal reduction in left ventricular ejection fraction (LVEF) (−3% ± 6% and −5% ± 5%); 69% and 93% of participants had at least one NYHA class improvement; Kansas City Cardiomyopathy Questionnaire–Clinical Summary Score improved by 15 ± 16 and 16 ± 16 points. Treatment-emergent serious adverse events (TESAEs) occurred in 36 (12.2%) patients; no deaths, heart failure, or events considered related to aficamten were reported. One (0.3%) patient terminated therapy due to a TESAE (ischemic colitis). LVEF<50% occurred in 10 (3.4%) patients [exposure-adjusted incidence rate (EAIR): 2.9 per 100 patient-years] with 2 having non-serious mild/moderate dyspnoea. No treatment interruptions for LVEF<50%, and no events of LVEF<40% occurred. New-onset atrial fibrillation occurred in seven (2.4%) patients (EAIR 2.0 per 100 patient-years).

Conclusions:

Extended aficamten treatment in patients with symptomatic oHCM yielded early and sustained hemodynamic and clinical responses with low incidences of new-onset atrial fibrillation and LVEF<50%.

2026-06-01·DRUGS

Aficamten: First Approval

Review

作者: Shirley, Matt

Aficamten (MYQORZO™) is a small-molecule cardiac myosin inhibitor being developed by Cytokinetics for the treatment of hypertrophic cardiomyopathy (HCM). Supported by the findings of the phase III, randomised, double-blind, placebo-controlled SEQUOIA-HCM trial, in December 2025 aficamten was approved in both China and the USA to improve functional capacity and symptoms in adults with symptomatic obstructive HCM (oHCM). Subsequently, in February 2026, aficamten was also approved in the EU for the treatment of symptomatic oHCM in adult patients. Aficamten is also in phase III evaluation for use in the treatment of non-obstructive HCM (nHCM) in adults. This article summarises the milestones in the development of aficamten leading to this first approval for symptomatic oHCM.

689

项与阿夫凯泰相关的新闻（医药）

2026-07-31

·Firstwordpharma

Three's an IPO crowd: biotech trio set to raise $575M in total

Gearing up for their public debuts, a trio of biotechs have set terms for their respective offerings this week, which collectively could raise close to $600 million. Lining up to make a run at the IPO window are cardiology company Braveheart Bio, inflammatory disease–focused Attovia and Vogenx, which is advancing an SGLT1 inhibitor for gastric and metabolic conditions. The three companies are part of a cohort of seven total biotechs that joined the IPO queue in the third quarter, after a gangbusters first half. They trail behind Apnimed, which set terms for a $150-million IPO earlier this week, and Scribe Therapeutics, the first biotech to make its debut in the second half with a $128.7-million raise. Still waiting in the wings are Latigo Biotherapeutics and BlossomHill Therapeutics.For related IPO analysis, see Spotlight On: Investors regain appetite for biotech IPOs.Braveheart's cardiac myosin betThe largest raise of the latest bunch could go to Braveheart, which proposed to sell 18.8 million shares at a range of $15 to $17 each. At the midpoint, the firm would raise $300 million and be valued at more than $1.1 billion. With its IPO cash, the biotech plans to launch a pair of Phase III trials evaluating its sole programme, BHB-1893, in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). Braveheart in-licensed ex-China rights to the oral cardiac myosin inhibitor in a deal last year with Jiangsu Hengrui Pharmaceuticals worth up to $1.1 billion.If successful in obstructive HCM, BHB-1893 will compete with rival cardiac myosin inhibitors Camzyos (mavacamten) from Bristol Myers Squibb and Cytokinetics' Myqorzo (aficamten).Attovia's ATTOBODIESAttovia is targeting the next-largest offering, having proposed to sell 12.5 million shares at $15 to $17 each. The company would raise $200 at the midpoint and garner a valuation of more than $600 million. The biotech is developing a trio of programmes called ATTOBODIES — biparatopic biologics that use spatial positioning technology to attain picomolar binding affinity. The IPO proceeds will help Attovia next year launch a Phase II trial evaluating lead candidate ATTO-1310 — an ATTOBODY-based IL-31–inhibiting Fc-fusion protein — for chronic pruritus and high-itch atopic dermatitis (AD).The company also has two preclinical programmes. ATTO-2306 is an ATTOBODY-based IL-13/IL-31–targeting bispecific for AD. while ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein designed to block TL1A, IL-23 and integrin a4ß7, could help treat inflammatory bowel disease.Vogenx's SGLT1 inhibitorThe third company looking to go public is Vogenx, which is aiming to sell 6.3 million shares at a range of $11 and $13. At the midpoint, it would raise $75 million and secure a valuation of more than $165 million. The offering will help fund the Phase IIb EMERGE study of its lead candidate mizagliflozin, an oral small-molecule inhibitor of SGLT1, a transporter in the gastrointestinal tract that moves dietary glucose into the bloodstream. Vogenx is developing mizagliflozin for post-bariatric hypoglycaemia (PBH), a side effect of bariatric weight-loss surgeries that causes low blood sugar after eating and can lead to confusion, anxiety, shaking and even fainting. It is also studying the asset for gastroparesis and GIP-dependent Cushing’s syndrome (GDCS).

临床2期IPO临床1期

2026-07-30

·今日头条

中国原研骨髓纤维化疗法获批：全球首个抗纤维化一线疗法，赛诺菲15.3亿美元获授权

> 骨髓纤维化——一种让骨髓逐渐被疤痕组织吞噬的血液疾病——过去，一线治疗药物鲁索替尼（芦可替尼）虽然能缓解脾脏肿大和全身症状，却有一个让人无奈的事实：它无法阻止纤维化进程，疾病依然在悄悄恶化。 2026年2月，一款名为**安煦®（罗伐昔替尼片）**的中国原研新药获批上市，打破了这一局面。它是全球首个同时作用于炎症和纤维化两条通路的骨髓纤维化一线疗法，被行业视为“下一代方向”。 ## 0到1的突破，才是关键如果把骨髓纤维化比作一场火灾，传统的JAK抑制剂就像消防员——能扑灭可见的火焰（炎症），但无法阻止建筑结构本身被烧毁（纤维化）。罗伐昔替尼的独特之处，在于它多了一个“救火+加固”的能力。它的靶点设计可以理解为“双钥匙锁”：一把钥匙（JAK抑制）锁住JAK-STAT炎症通路，阻断免疫风暴；另一把钥匙（ROCK抑制）则直接作用于ROCK纤维化通路，试图阻止甚至逆转骨髓中的纤维化进程。现有的一线药物鲁索替尼仅能抑制JAK通路，对纤维化本身无能为力。 ## 从中国实验室到全球舞台罗伐昔替尼的研发方是**正大天晴**（中国生物制药子公司），它完成了从靶点发现到中国注册上市的全流程，属于中国自主研发的**1类化学新药**。 2025年，这笔资产被全球制药巨头赛诺菲相中。双方签署的独家全球许可协议显示：赛诺菲支付**首付款1.35亿美元**，加上开发、注册及销售里程碑，总交易金额最高可达**15.3亿美元**。赛诺菲获得该药全球开发、生产及商业化的独家权益，正大天晴则负责早期研发与中国境内的上市申报。 ## 尚未上市，但已蓄势待发赛诺菲计划在**2026年11月的第九届中国国际进口博览会**上完成该药的“全球首秀”。但参考赛诺菲过往的“进博速度”——上一届进博会全球首秀的阿夫凯泰片，在获批后约三个月开出全国首批处方，罗伐昔替尼的落地节奏值得期待。 ## 中国创新药：从“跟随”到“首创” 罗伐昔替尼的获批它验证了本土研发在难治性血液疾病领域具备全球竞争力，也标志着中国药企不再只做“改良者”，而是开始输出“全球首发”的解决方案。赛诺菲大中华区总裁施旺曾表示：“中国市场的核心优势在于高效与经济，不仅速度快，而且成本相对较低。”这种“中国研发、全球授权”的模式，正在成为跨国药企与中国本土创新之间的新常态。对于骨髓纤维化患者而言，罗伐昔替尼的到来意味着：**一线治疗第一次有了“抗纤维化”的选项，而不仅仅是“缓解症状”。** 当一款药物既能灭火又能修墙，生存的希望才真正向前迈进了一步。

2026-07-30

·BioSpace

Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales

Authorisation from MRHA and Recommendation from NICE This announcement is intended for business and financial media and investors only SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted MYQORZO® ( aficamten ) a marketing authorisation across the United Kingdom for the treatment of symptomatic (New York Heart Association, NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in eligible adult patients. At the same time the National Institute for Health and Care Excellence (NICE) has issued guidance recommending aficamten for use in eligible adult patients in England and Wales. The guidance from NICE states that aficamten can be used as an option to treat symptomatic oHCM in eligible adults with a NYHA class of II to III. It can only be used as an add-on to individually optimised standard care including beta-blockers, non-dihydropyridine calcium-channel blockers or disopyramide, or alone if these treatments are contraindicated, and if the company provides it according to the commercial arrangement. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); “We are pleased to have secured a marketing authorisation for aficamten and to see positive guidance from NICE for eligible adult patients in England and Wales,” said Joseph Dagher, Senior Vice President and Head of Europe, Cytokinetics. “We are grateful for the collaborations that made this review possible for concurrent MHRA and NICE decisions and are committed to supporting access for eligible adult patients through the NHS upon availability expected later this year.” The MHRA assessment of aficamten drew on data from SEQUOIA-HCM, a phase 3 multicentre double-blind placebo-controlled randomised study in 282 adults (142 aficamten , 140 placebo) treated for 24 weeks. 1 The primary endpoint was the change from baseline to Week 24 in peak oxygen uptake (pVO 2 ) measured by cardiopulmonary exercise testing. Aficamten resulted in a statistically significant improvement in peak oxygen uptake compared with placebo (mean change 1.8 mL/kg/min with aficamten versus 0.0 mL/kg/min with placebo; least squares mean difference 1.7 mL/kg/min, 95% confidence interval 1.0 to 2.4; p < 0.001). 1 Further information, including efficacy and safety data, is provided in the aficamten Summary of Product Characteristics. 2 The most commonly reported adverse reactions with aficamten were hypertension (7.7%), palpitations (7.0%), dizziness (4.2%) and systolic dysfunction (3.5%). 2 ▼ MYQORZO ( aficamten ) is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at yellowcard.mhra.gov.uk or by searching for MHRA Yellow Card in the Google Play or Apple App Store. About Aficamten Aficamten is a cardiac myosin inhibitor authorised in the United Kingdom for the treatment of symptomatic (NYHA class II-III) oHCM in eligible adult patients. In patients with oHCM, myosin inhibition with aficamten reduces cardiac contractility and, consequently, left ventricular outflow tract (LVOT) obstruction. Aficamten has a predictable exposure-response relationship and a reversible mechanism of action. 1 About Obstructive Hypertrophic Cardiomyopathy Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle becomes abnormally thick. In oHCM, thickened heart muscle blocks blood flow, and the inside of the left ventricle becomes smaller, stiffer and less able to relax and fill with blood. This limits the heart's pumping function, leading to reduced exercise capacity and a variety of symptoms. HCM is the most common monogenic inherited cardiovascular disorder, affecting approximately 1 out of 500 Europeans, according to European Society of Cardiology guidelines. 3 Approximately half of patients with HCM have oHCM. 4 People with oHCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease. 5 People with oHCM are at risk of potentially fatal ventricular arrhythmias, which is one of the leading causes of sudden cardiac death in younger people or athletes. 6 A subset of patients with oHCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology and advancing a pipeline of potential new medicines. For additional information about Cytokinetics, visit and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the enrollment, expected results or timing of completion of any of our clinical trials, the clinical meaningfulness, persuasiveness or interpretation of clinical trial results, including for purposes of regulatory approval, labeling, or market acceptance, the results of long-term, secondary or exploratory analyses, including analyses of time to first cardiovascular event, statements relating to our ability to obtain regulatory approval for aficamten in nonobstructive hypertrophic cardiomyopathy in any particular date, if ever, the number of patients comprising the eligible treatment population for aficamten , or market acceptance of aficamten for the treatment of nonobstructive hypertrophic cardiomyopathy. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission including the risk factors included in Cytokinetics' most recent Annual Report on Form 10-K and subsequent reports filed with the SEC. CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union and the United Kingdom. References Maron MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. doi:10.1056/NEJMoa2401424 MYQORZO ( aficamten ) UK Summary of Product Characteristics. Available from Cytokinetics upon request ESC Clinical Practice Guidelines. ESC European Society of Cardiology. Accessed July 23, 2025. Butzner M, et al. Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023. JACC Adv. 2026;5(2):102552. doi:10.1016/j.jacadv.2025.102552 Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260. Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757

100 项与阿夫凯泰相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
梗阻性肥厚型心肌病	中国	Cytokinetics, Inc.	2025-12-16

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非梗阻性肥厚型心肌病	临床3期	美国	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	中国	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	日本	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	阿根廷	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	澳大利亚	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	巴西	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	加拿大	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	丹麦	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	法国	Cytokinetics, Inc.	2023-08-30
非梗阻性肥厚型心肌病	临床3期	德国	Cytokinetics, Inc.	2023-08-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05767346 (MAPLE-HCM, CTgov)	临床3期	梗阻性肥厚型心肌病	175	aficamten (Aficamten)	願願鏇鹽鹹膚艱簾淵齋(願築遞艱鏇鹹餘憲觸獵) = 鏇遞範觸選淵鬱壓積繭膚鏇鹹糧獵膚顧製艱醖 (積夢衊襯鹹鏇醖鹹餘壓, 2.767) 更多	-	2026-06-09
				Metoprolol (Metoprolol)	願願鏇鹽鹹膚艱簾淵齋(願築遞艱鏇鹹餘憲觸獵) = 廠鑰簾積淵鹹壓齋憲壓膚鏇鹹糧獵膚顧製艱醖 (積夢衊襯鹹鏇醖鹹餘壓, 2.186) 更多
NCT05186818 (SEQUOIA-HCM, CTgov)	临床3期	梗阻性肥厚型心肌病	282	Aficamten (Aficamten up to 20 mg)	鏇窪選構衊鹹築壓鏇鹽(膚窪鹹鏇襯壓簾齋遞窪) = 網艱蓋範選膚壓廠簾鑰顧繭鹽鏇鹹壓繭鏇淵醖 (構獵遞壓夢廠顧鬱夢衊, 0.25) 更多	-	2026-03-03
				Placebo to match aficamten (Placebo to Match Aficamten)	鏇窪選構衊鹹築壓鏇鹽(膚窪鹹鏇襯壓簾齋遞窪) = 鏇繭壓衊製範齋蓋鹽繭顧繭鹽鏇鹹壓繭鏇淵醖 (構獵遞壓夢廠顧鬱夢衊, 0.25) 更多
NCT04219826 (REDWOOD-HCM Cohort 4 \| REDWOOD-HCM, CTgov)	临床2期	肥大型心肌病	96	CK-3773274 (Cohort 1 (oHCM) - Aficamten)	餘壓積選範壓鬱廠壓範 = 窪鬱餘遞願鑰範積鏇夢淵範夢齋獵顧淵壓製選 (廠夢願夢鬱壓觸齋鏇齋, 窪夢願觸鹹獵壓築窪築 ~ 範簾鹽築鹽遞觸簾糧蓋) 更多	-	2026-02-24
				CK-3773274 (Cohort 2 (oHCM) - Aficamten)	餘壓積選範壓鬱廠壓範 = 鹹齋蓋廠鏇製繭憲衊製淵範夢齋獵顧淵壓製選 (廠夢願夢鬱壓觸齋鏇齋, 夢獵憲鏇夢窪觸鹹醖糧 ~ 齋齋觸膚齋顧獵糧構觸) 更多
NCT06412666 \| NCT05186818 (CEDAR-HCM, Pubmed \| Circ Heart Fail)	临床3期	梗阻性肥厚型心肌病	65	Aficamten	齋築製鑰糧獵獵壓衊範(顧夢齋壓簾鹽築繭築鹽) = 餘遞淵積壓鹹繭製窪窪鏇範鏇鹹廠鑰膚觸範廠 (簾蓋廠淵膚壓窪積構襯 )	积极	2025-12-05
NCT05767346 (MAPLE-HCM, Pubmed \| J Am Coll Cardiol)	临床3期	梗阻性肥厚型心肌病	175	Aficamten 5 to 20 mg	餘築鏇衊糧鏇積積簾夢(簾鬱鹹選憲夢繭壓顧窪) = 鏇繭蓋觸齋顧範廠壓繭膚遞蓋願構艱鏇鹽夢齋 (膚淵築窪選獵積築鹹醖 ) 更多	积极	2025-12-01
				Metoprolol 50 to 200 mg	-
NCT05767346 (MAPLE-HCM, Pubmed \| J Am Coll Cardiol)	临床3期	梗阻性肥厚型心肌病	175	Aficamten	夢窪壓齋積衊製網積襯(膚願築鬱觸簾壓餘簾鑰): Difference = 7.8 (95.0% CI, 3.3 ~ 12.3), P-Value = < 0.001 更多	积极	2025-11-01
				Metoprolol
NCT05767346 (MAPLE-HCM, Pubmed \| J Am Coll Cardiol)	临床3期	梗阻性肥厚型心肌病	175	Aficamten	夢製構構糧醖壓構積網(願艱壓廠簾蓋鹽窪鑰遞) = 鬱艱製鹽顧簾築積壓醖範糧願築築壓鏇鹹糧製 (鑰獵願廠積艱獵憲觸鏇 ) 更多	积极	2025-11-01
				Metoprolol	夢製構構糧醖壓構積網(願艱壓廠簾蓋鹽窪鑰遞) = 簾繭窪夢襯醖廠鬱鹽簾範糧願築築壓鏇鹹糧製 (鑰獵願廠積艱獵憲觸鏇 ) 更多
NCT05767346 (MAPLE-HCM, Company_Website) 人工标引	临床3期	梗阻性肥厚型心肌病	-	Aficamten	鑰鏇壓網蓋積選構選獵(獵糧鑰簾艱遞範遞遞選) = 願選餘構膚鏇構鑰醖衊構衊窪窪鬱鹽襯選齋餘 (構膚鹹糧鏇繭顧網糧遞 ) 更多	优效	2025-09-29
				Metoprolol	-
NCT04848506 (FOREST-HCM, Company_Website) 人工标引	临床2/3期	非梗阻性肥厚型心肌病	34	Aficamten (post-REDWOOD-HCM Cohort 4)	夢築獵鹹選鏇鏇蓋積願(願網鏇顧醖鹽築獵壓壓) = 窪衊構簾觸願衊網選鹽鏇顧壓鬱積廠醖網選願 (醖淵夢衊壓遞夢願糧簾 ) 更多	积极	2025-09-29
NCT05767346 (MAPLE-HCM, Pubmed \| N Engl J Med) 人工标引	临床3期	梗阻性肥厚型心肌病	175	Aficamten	壓築積廠糧願網網壓築(醖淵憲鬱襯顧糧襯繭獵) = 簾衊壓蓋鹽艱蓋鏇膚醖網壓鏇廠鹹憲獵鏇簾壓 (壓鑰膚顧獵壓餘蓋構製, 0.5 ~ 1.7)	优效	2025-09-11
				Metoprolol	壓築積廠糧願網網壓築(醖淵憲鬱襯顧糧襯繭獵) = 積遞範鑰壓膚鹽鑰鏇襯網壓鏇廠鹹憲獵鏇簾壓 (壓鑰膚顧獵壓餘蓋構製, -1.7 ~ -0.8)